RASSF1 and benign prostatic hyperplasia: A pilot study analysis of blood plasma samples from 90 healthy individuals (controls), 40 BPH patients, and 39 PCa patients revealed a gradual increase in cfDNA methylation for control, BPH, and PCa cohorts using biomarkers RASSF1A, MIR129-2, NRIP3, and SOX8.